Las Vegas, NV
Ketamine Therapy clinics in Las Vegas
Las Vegas has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Nevada permits ketamine infusions under physician supervision; Spravato REMS clinics operate in Las Vegas and Reno. Most Las Vegas clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Las Vegas only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Las Vegas, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Las Vegas sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Las Vegas ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Wellness & Hormones Avenue
- IV Therapy
- Ketamine Therapy
- Arthritis Treatment
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
Klarity Ketamine Clinic
- NAD IV Therapy
- Vitamin IV Therapy
- Neurofeedback Therapy
- Ketamine Therapy
Suarez Physical Therapy
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- Shockwave Therapy
AnywhereClinic
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Mind Brain Institute TMS and Psychiatry Services
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Ketamine Therapy
Regulatory context
A note on Nevada's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
SB 242 / Psychedelic Medicines Working Group (2023)
Established a working group to study regulated access to psilocybin and MDMA therapy; report and follow-on legislation pending. -
Nevada Uniform Controlled Substances Act
Mirrors federal scheduling.
Nevada enforces federal scheduling. The Nevada State Board of Medical Examiners oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Nevada PMP requires controlled substance reporting.